Opportunities
Search

Summary: The fiscal year 2026 (FY26) Military Burn Research Program (MBRP) Discovery Award supports innovative, untested, groundbreaking research that provides new insights and explores early concepts in combat-relevant burn care that provide the foundation for future translational and/or clinical research. The proposed project may be exploratory, hypothesis-driven, or hypothesis-generating research, but must be novel and must be based on a strong scientific rationale and a well-developed study design. Distinctive Features: The focus of this award mechanism is innovation. Proposed research should lay the groundwork for future avenues of scientific investigation or product development in the area of combat-relevant burn care. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for groundbreaking future research projects.

Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Clinical Research Award (CRA) supports clinical research that evaluates disease-specific factors and interventions. Research is intended to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Research addressing any and all types of arthritis is encouraged.Applications must address one of two FY26 ATRP CRA Focus Areas: Prevention and Early Diagnosis, or Treatment and Mitigation of Disease Progression/Burden.Distinctive Features: The FY26 ATRP CRA offers funding for two research levels. It is the responsibility of the applicant to select the level that aligns with the scope of the proposed research.• Research Level 1: Applications proposing clinical research or early-phase/pilot clinical trials, to include new or emerging research that is not ready for a full-scale randomized controlled clinical trial.• Research Level 2: Applications proposing a full-scale clinical trial.Applications should include a community collaborator (e.g., patient/care partner, community-based organization consultant) who will provide advice and consultation during study design and throughout study planning and implementation. The ATRP encourages a community collaborator for Research Level 1 applications and requires a community collaborator for Research Level 2 applications.Preliminary and/or published data are required.

Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions. Research funded under this award mechanism will be hypothesis-driven, high-impact applied research that is relevant to Service Members, Veterans, their Families and the American public. Research addressing any and all types of arthritis is encouraged.Distinctive Features: The FY26 ATRP TRA mechanism is intended to support preclinical or animal research and may not be used for clinical research or clinical trials. Basic research, as defined in Section 3.1.2, is not allowed. A key aspect of this award mechanism is impact. The application should explicitly state how outcomes of the proposed research will significantly advance arthritis research, particularly in accelerating critical findings into clinically relevant solutions.Preliminary and/or published data, originating from research conducted by the applicant(s) or others, is required.

Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Idea Development Award (IDA) is to support conceptually innovative research that could lead to impactful discoveries or significant advancements that will accelerate progress toward reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or the quality of life. Applications should propose research that is conceptually innovative, introduces a new concept or question, challenges existing paradigms, approaches issues from a new perspective, or exhibits other uniquely creative qualities; and should not merely be a next logical step or an incremental advance on published data or ongoing research. Distinctive Features: A Career Development Option is available to eligible early-career investigators who propose to conduct impactful mechanism-relevant research under the mentorship of an experienced tick-borne disease researcher(s). Applications submitted under the IDA – Career Development Option (IDA-CDO) will be reviewed using separate, career development-specific evaluation criteria by a separate, dedicated peer review panel; and are subject to a lower cost limit than those submitted under the standard IDA.https://cdmrp.health.mil/pubs/press/2026/tbdrppreann

Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award (TDRA) is to support product-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or quality of life. Treatment-focused applications should be therapeutic evaluation studies designed to advance new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings.  https://cdmrp.health.mil/pubs/press/2026/tbdrppreann

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Career Development Award supports early-career, independent investigators and/or the transition of established investigators from other research fields to conduct innovative, high-impact ideas or early-phase, proof-of-principle clinical trials with the potential to have a major impact on autism.Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Career Development Award Areas of Interest or provide justification that the proposed research addresses a critical problem, question, or need in autism.FY26 Career Development Award submissions with a pilot clinical trial component are required to include community collaborations to optimize research impact. Applications are expected to name at least one community partner (e.g., an Autistic individual or caregiver, representatives of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of autism. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Clinical Trial Award Areas of Interest.Partnering Principal Investigator (PI) Option for Early-Career Investigator: The FY26 Clinical Trial Award mechanism is offering a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in autism clinical trial research.FY26 Clinical Trial Award submissions are required to include community collaborations to optimize research impact. Research teams are therefore required to establish and utilize effective and equitable collaborations and partnerships with community members to maximize the translational and impact potential of the proposed research. Applications to the FY26 ARP Clinical Trial Award are expected to name at least one community partner (e.g., A...

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for Autistic individuals. This award mechanism is designed to support innovative ideas with the potential to yield impactful data and new avenues of investigation.Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Idea Development Award Areas of Interest or provide justification that the proposed research addresses a critical problem, question, or need in autism.Partnering Principal Investigator (PI) Option: The Partnering PI Option is structured so that two investigators, each of whom will be designated as a PI, will work synergistically on a single project. The results of this partnering project should significantly advance the research beyond what would be possible through individual efforts.

In 2016, the National Science Foundation (NSF) unveiled a set of “Big Ideas,” 10 bold, long-term research and process ideas that identify areas for future investment at the frontiers of science and engineering (see https://www.nsf.gov/news/special_reports/big_ideas/index.jsp). The Big Ideas represent unique opportunities to position our Nation at the cutting edge of global science and engineering leadership by bringing together diverse disciplinary perspectives to support convergence research. As such, when responding to this solicitation, even though proposals must be submitted to the Directorate for STEM Education (EDU) / Division of Equity for Excellence in STEM (EES), once received, the proposals will be managed by a cross-disciplinary team of NSF Program Directors. The INCLUDESInitiative is a comprehensive, national effort to enhance U.S. leadership in science, technology, engineering, and mathematics (STEM) discovery and innovation, focused on NSF’s commitment to ensuring accessibility and inclusivity in STEM fields, as communicated in the NSF Strategic Plan for Fiscal Years (FY) 2022 - 2026. The vision of the INCLUDES Initiative is to catalyze the STEM enterprise to work collaboratively for inclusive change, resulting in a STEM workforce that reflects the Nation’s population. More specifically, the INCLUDES Initiative seeks to motivate and accelerate collaborative infrastructure building to sustain systemic change to broaden participation in STEM fields at scale.Significant advancement of the INCLUDES Initiative's goalswill result in a new generation of STEM talent a...

The CHIPS Incentives Program aims to catalyze long-term economically sustainable growth in the domestic semiconductor industry in support of U.S. economic and national security. This is the second Notice of Funding Opportunity under this program and seeks applications for projects for the construction, expansion, or modernization of commercial facilities for semiconductor materials and manufacturing equipment. For more information, additional resources, and instructions on how to apply, please visit chips.gov. Note that all applications must be submitted through the CHIPS Incentives Portal at https://applications.chips.gov. If you have any questions on how to apply, please email apply@chips.gov.

Congress in 1988 established the Fair Housing Initiatives Program (FHIP) with a purpose of providing funding to entities to work alongside HUD to "prevent or eliminate discriminatory housing practices" 42 USC § 3616a(a). FHIP provides funds to eligible organizations through competitive grants. under several initiatives.The overarching purpose of the FHIP Education and Outreach Initiative (EOI) is to educate the public, housing providers and other stakeholders about their rights and obligations under provisions of fair housing laws, through the development, implementation, carrying out and coordinating or education and outreach programs. 42 USC § 3616a(d)(1); 24 CFR 125.301(a).The National Media Campaign component (EOI-NMC) is "designed to provide a centralized, coordinated effort for the development and dissemination of fair housing media products." 42 USC § 3616a(d)(1). A portion of NMC funds are specifically meant to increase participation in the annual national fair housing month. Under a cooperative agreement, HUD will exercise the right to approve, and have substantial involvement in, all proposed deliverables, as well as the Work Plan or Statement of Work (SOW).The General Component (EOI-GC) is designed to carry out projects programs that prevent or eliminate discriminatory housing practices by establishing or supporting regional, local, and community- based education and outreach activities, events, and programs. For grants and cooperative agreements, HUD will conduct monitoring reviews, request quarterly reports, and approve all proposed deliverables as documented i...

Congress amended the Fair Housing Act in 1988 to establish the Fair Housing Initiatives Program (FHIP) to provide funding to entities to work alongside HUD to "prevent or eliminate discriminatory housing practices" 42 USC §3616a (a). Congress determined in 1987, and has affirmed each year since then through appropriations, that HUD can only achieve its fair housing mission and obligations through supporting a network of organizations helping to educate the public and enforce fair housing rights. Initially a demonstration program, Congress made FHIP permanent in 1992 through the Housing and Community Development Act of 1992. The program was expanded in 1992 to address building capacity in unserved areas, establish a national media campaign, and fund a National Fair Housing Month.FHIP provides funds to eligible organizations through competitive grants under four initiatives: the Fair Housing Organizations Initiative (FHOI), the Private Enforcement Initiative (PEI), the Administrative Enforcement Initiative (AEI), and the Education and Outreach Initiative (EOI).This NOFO funds the PEI to provide grants to a nationwide network of eligible private, non-profit fair housing enforcement organizations to conduct testing and investigate violations of and enforce the Fair Housing Act, and State or local laws with equivalent rights and remedies.

The Topology program supports research on algebraic topology, including chromatic, equivariant, motivic, and (un)stable homotopy, homology and cohomology theories; bordism and K-theory; topological manifolds; knots and links; geometric topology; differential topology; transformation groups; topological quantum field theories; contact and symplectic structures; infinity and model categories; and topological data analysis. Conferences Topology proposals for conferences, workshops, summer/winter schools, and similar activities must be submitted to PD 22-1267 using the "Conference" or “Travel” proposal type in research.gov. The program’ssubmission windows for conference/travel proposalsare September 1-30 and April 1-30. Proposals with budgets not exceeding $50,000 should be submitted during a submission window that occursat least six months prior to the event. Proposals with budget requests that exceed $50,000 should be submitted during a submission window that occursat least eight months prior to the event. Principal Investigators should carefully read the relevant sections of the PAPPG to obtain important information regarding the substance of such proposals and note the additional requirements for travel support requests for international events.

The program in Geometric Analysis supports research on differential geometry and its relation to partial differential equations and variational principles; geometric methods in modern mathematical physics; symplectic geometry; geometric group theory; geometric data analysis; aspects of global analysis, including convex, complex, integral, and information geometries; and related geometric topics. Conferences Geometric Analysis proposals for conferences, workshops, summer/winter schools, and similar activities must be submitted to PD 22-1265 using the "Conference" or “Travel” proposal type in research.gov. The program’s submission windows for conference/travel proposals are September 1-30 and April 1-30. Proposals with budgets not exceeding $50,000 should be submitted during a submission window that occursat least six months prior to the event. Proposals with budget requests that exceed $50,000 should be submitted during a submission window that occursat least eight months prior to the event. Principal Investigators should carefully read the relevant sections of the PAPPG to obtain important information regarding the substance of such proposals and note the additional requirements for travel support requests for international events.

The Directorate for Social, Behavioral and Economic Sciences (SBE) offers Postdoctoral Research Fellowships to encourageindependence earlyin the fellow'scareerby supporting his or herresearch and training goals.The research and training plan of each fellowship must address important scientific questions within thescope of the SBE directorate and the specific guidelines in this solicitation. The SPRF program offers two tracks: (I) Fundamental Research in the SBE Sciences (SPRF-FR) and (II) Broadening Participation in the SBE Sciences (SPRF-BP). See the full text of the solicitation for a detailed description of these tracks.

Summary: The fiscal year 2026 (FY26) Bone Marrow Failure Research Program (BMFRP) Resource Development Award (RDA) supports the development of a multiomic atlas generated from well-annotated human bone marrow failure (BMF) samples, with omic data derived from marrow specimens. The resulting dataset should serve as an open-access, durable resource for the BMF research and clinical communities and is expected to facilitate key discoveries that advance the understanding of BMF diseases.Distinctive Features: The application must include a robust Data Resource Sharing Plan that describes the means and timeline by which the fully developed resource will be made available to the scientific and clinical community.

Summary: Supports studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in bone marrow (BMF) failure research and/or patient care. Investigator-Initiated Research Award (IIRA) applications may involve translational and clinical research including studies in preclinical models, research with human data and/or anatomical substances, and research with human subjects, as well as correlative studies associated with a clinical trial(s); however, this award mechanism does not support clinical trials. IIRA applications may also support Investigational New Drug (IND)-enabling efforts such as lead compound characterization, and assessments of formulation and stability, absorption, distribution, metabolism and excretion, dose/response and toxicology.Distinctive Features:This funding mechanism allows for a partnering Principal Investigator (PI). Only the initiating PI will submit a pre-application, but both PIs will need to submit full applications. The partnering PI application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.This award mechanism requires preliminary data relevant to the proposed project. Applications can support clinical research studies; however, this mechanism does not allow clinical trials.

Summary: The BMFRP Idea Development Award (IDA) is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the BMFRP’s vision of understanding and curing BMF diseases.Distinctive Features:This funding opportunity is open to Established Investigators (EIs) and Early-Career Investigators (ECIs). Reviewers will assess Principal Investigators (PIs) using distinct review criteria based on their eligibility as an EI or ECI.Preliminary data is not required. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.

Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research. Research must address at least one of the four FY26 PRP Focus Areas.Distinctive Features:·        Partnering Principal Investigator (PI) Option: Allows for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as Partnering PI(s), with a maximum of two Partnering PIs.·        Preliminary data are required.·        Clinical trials are allowed.

Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Early Investigator Research Award (EIRA) supports Parkinson’s disease (PD) research for investigators in the early stages of their careers. The FY26 EIRA offers two funding levels, which align to the research career stage of the Principal Investigator (PI). Funding Level 1 (for fellows) requires the investigator to receive guidance from a designated Mentor, whereas Funding Level 2 (for early-career independent investigators) does not. Proposed research must address at least one of the four FY26 PRP Focus Areas.Distinctive Features:·        The Early Investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience.·        Funding Level 1: Applications must include at least one Mentor appropriate to the proposed research project who has experience in PD research and mentoring, as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a PD researcher. Preliminary data are encouraged but not required.·        Funding Level 2: Mentor not required. Preliminary data are required.·        Clinical trials are not allowed.

This program element does not have a proposal due date. Proposals may be submitted at any time, pending certain eligibility timing issues related to resubmissions and duplicate proposal avoidance, see the program element text and appropriate overview appendix (e.g., B.1 or C.1). The date shown of 8/1/2026 is the last day that proposals may be submitted subject to the ROSES-25 rules and the current GCAM. The ROSES-26 version of this program element is planned to overlap with this ROSES-25 version by a few weeks, allowing continuous submission of proposals across ROSES years. NOTICE: Research security training required starting August 5, 2026. All PIs and any Co-Is that would spend ≥ 10% time on a proposed grants or cooperative agreements must certify they have taken research security training. NASA will be satisfied with the four online research security training modules on the National Science Foundation's (NSF) Research Security Training website at https://www.nsf.gov/research-security/training or the SECURE Center condensed version of the four modules at https://www.secure-center.org/ctm NOTICE: Amended July 2, 2026. Table C.2-1: Submission and Review Dates in Section 3.1 has been updated and a new row with a new final cut-off date of November 12, 2026, has been added. In addition, this amendment reminds proposers of two important upcoming process changes: Potential proposers are reminded in Section 3.1 that for any proposal for federal assistance submitted > August 5, 2026, PIs and any Co-Is that would spend > 10% time on a proposed grants or cooperative agreements must...

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Investigator-Initiated Research Award (IIRA) supports studies that have the potential to make an important contribution to spinal cord injury (SCI) research, patient care and/or quality of life. May focus on any phase of research from basic through translational science, though studies that focus solely on identifying intervention targets are discouraged.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two Principal Investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas.   Distinctive Features: ·       For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant Regulatory Agency by the CTA application submission deadline. In addition, applicants must provide documentation of communication from the Regulatory Agency indicating that the IND/IDE or equivalent is active/safe to proceed by March 1, 2027, in order for the CTA application to be considered for funding. Refer to Attachment 7: Regulatory Strategy for further details. ·       Scored peer review criteria include Clinical Impact; Research Strategy and Feasibility; Recruitment, Accrual, Retention; Regulatory Strategy and Transition Plan; Statistical Plan and Data Analysis; Ethical Considerations; Personnel and Communication. ·       Programmatic review criteria include adherence to the intent of the CTA, contribution to program portfolio, relative impact and relevance to military health. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of spinal cord injury (SCI).Distinctive Features: This funding opportunity contains an Early-Career Partnership Option, which allows for two Principal Investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the Initiating PI will submit a pre-application, but all PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.Applications to this funding opportunity must name at least two spinal cord injury (SCI) community partners (e.g., SCI Lived-Experience Consultants, representatives of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA) supports basic through early translational research that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction related to military exposure. The IIRA may be used to support preclinical studies and/or clinical research. Research must align with at least one of the FY26 VRP Focus Areas. The IIRA cannot be used to support clinical trials. Distinctive Features: ·        The IIRA offers two Funding Levels to support research at different stages and the exploration/development of ideas of different maturity levels. ·        Funding Level 2 includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI. ·        Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, and Personnel. ·        Programmatic review criteria include adherence to the intent of the IIRA, contribution to the VRP portfolio, relative impact, and relevance to military health. ·        The VRP may share FY26 IIRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration. https://cdmrp.health.mil/pubs/press/2026/vrppreann